AstraZeneca meets in Phase III COPD trials

AstraZeneca plc (LSE:AZN; NYSE:AZN) said PT003 met the primary endpoint of the Phase III PINNACLE 1 and PINNACLE 2 studies to treat chronic obstructive pulminary disease (COPD).

In both trials, PT003 led to statistically significant improvements in trough forced expiratory volume in one second (FEV1) compared to AZ's PT001, PT005 and placebo. PT003 is a combination of PT001 and PT005, each of which also led to statistically significant improvements in trough FEV1 vs. placebo. AZ plans to submit a U.S. regulatory application this year, followed by a submission in the EU. ...